Literature DB >> 26090563

Impact of formulation and particle size on stability and immunogenicity of oil-in-water emulsion adjuvants.

Vidyashankara Iyer1, Corinne Cayatte, Bernardo Guzman, Kirsten Schneider-Ohrum, Ryan Matuszak, Angie Snell, Gaurav Manohar Rajani, Michael P McCarthy, Bilikallahalli Muralidhara.   

Abstract

Oil-in-water emulsions have gained consideration as vaccine adjuvants in recent years due to their ability to elicit a differentiated immunogenic response compared to traditional aluminum salt adjuvants. Squalene, a cholesterol precursor, is a natural product with immunostimulatory properties, making it an ideal candidate for such oil-in-water emulsions. Particle size is a key parameter of these emulsions and its relationship to stability and adjuvanticity has not been extensively studied. This study evaluates the effect of particle size on the stability and immunogenicity of squalene emulsions. We investigated the effect of formulation parameters such as surfactant concentration on particle size, resulting in particles with average diameter of 80 nm, 100 nm, 150 nm, 200 nm, or 250 nm. Emulsions were exposed to shear and temperature stresses, and stability parameters such as pH, osmolarity, size, and in-depth visual appearance were monitored over time. In addition, adjuvanticity of different particle size was assessed in a mouse model using Respiratory Syncytial Virus Fusion protein (RSV-F) as a model antigen. Temperature dependent phase separation appeared to be the most common route of degradation occurring in the higher particle sizes emulsions. The emulsions below 150 nm size maintained stability at either 5 °C or 25 °C, and the 80 nm diameter ones showed no measurable changes in size even after one month at 40 °C. In vivo studies using the emulsions as an adjuvant with RSV F antigen revealed that superior immunogenicity could be achieved with the 80 nm particle size emulsion.

Entities:  

Keywords:  RSV; adjuvants; emulsions; squalene; stability; surfactants; vaccines

Mesh:

Substances:

Year:  2015        PMID: 26090563      PMCID: PMC4517459          DOI: 10.1080/21645515.2015.1046660

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  28 in total

1.  GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults.

Authors:  Hayedeh Behzad; Anke L W Huckriede; Laura Haynes; Beth Gentleman; Krysta Coyle; Jan C Wilschut; Tobias R Kollmann; Steven G Reed; Janet E McElhaney
Journal:  J Infect Dis       Date:  2011-12-05       Impact factor: 5.226

Review 2.  Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion.

Authors:  Nathalie Garçon; David W Vaughn; Arnaud M Didierlaurent
Journal:  Expert Rev Vaccines       Date:  2012-03       Impact factor: 5.217

3.  MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020).

Authors:  Barbara C Baudner; Vanessa Ronconi; Daniele Casini; Marco Tortoli; Jina Kazzaz; Manmohan Singh; Lynn D Hawkins; Andreas Wack; Derek T O'Hagan
Journal:  Pharm Res       Date:  2009-03-03       Impact factor: 4.200

4.  AF03, an alternative squalene emulsion-based vaccine adjuvant prepared by a phase inversion temperature method.

Authors:  Marie-Françoise Klucker; François Dalençon; Patricia Probeck; Jean Haensler
Journal:  J Pharm Sci       Date:  2012-08-31       Impact factor: 3.534

5.  The Biological Significance of the Unsaponifiable Matter of Oils: Experiments with the Unsaturated Hydrocarbon, Squalene (Spinacene).

Authors:  H J Channon
Journal:  Biochem J       Date:  1926       Impact factor: 3.857

Review 6.  MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile.

Authors:  Audino Podda; Giuseppe Del Giudice
Journal:  Expert Rev Vaccines       Date:  2003-04       Impact factor: 5.217

7.  Experimental squalene adjuvant. I. Preparation and testing of its effectiveness.

Authors:  Judit Süli; Zdenek Benísek; Daniel Eliás; Stefan Svrcek; Anna Ondrejková; Róbert Ondrejka; Viera Bajová
Journal:  Vaccine       Date:  2004-09-03       Impact factor: 3.641

8.  An adjuvanted respiratory syncytial virus fusion protein induces protection in aged BALB/c mice.

Authors:  Anu Cherukuri; Kate L Stokes; Kathryn Patton; Howard Kuo; Kaori Sakamoto; Stacie Lambert; Elizabeth Stillman; Martin L Moore; Sujin Lee
Journal:  Immun Ageing       Date:  2012-10-02       Impact factor: 6.400

Review 9.  Strategic priorities for respiratory syncytial virus (RSV) vaccine development.

Authors:  L J Anderson; P R Dormitzer; D J Nokes; R Rappuoli; A Roca; B S Graham
Journal:  Vaccine       Date:  2013-04-18       Impact factor: 3.641

Review 10.  Squalene emulsions for parenteral vaccine and drug delivery.

Authors:  Christopher B Fox
Journal:  Molecules       Date:  2009-09-01       Impact factor: 4.411

View more
  10 in total

1.  Reversion of Multidrug Resistance by Co-Encapsulation of Doxorubicin and Metformin in Poly(lactide-co-glycolide)-d-α-tocopheryl Polyethylene Glycol 1000 Succinate Nanoparticles.

Authors:  Vahid Shafiei-Irannejad; Nasser Samadi; Roya Salehi; Bahman Yousefi; Mahdi Rahimi; Abolfazl Akbarzadeh; Nosratollah Zarghami
Journal:  Pharm Res       Date:  2018-04-18       Impact factor: 4.200

2.  Single-vial filovirus glycoprotein vaccines: Biophysical characteristics and immunogenicity after co-lyophilization with adjuvant.

Authors:  Kendall B Preston; Teri Ann S Wong; Albert To; Taylor E Tashiro; Michael M Lieberman; Alex Granados; Karen Feliciano; John Harrison; Jake Yalley-Ogunro; Hanne Andersen Elyard; Oreola Donini; Axel T Lehrer; Theodore W Randolph
Journal:  Vaccine       Date:  2021-08-13       Impact factor: 4.169

3.  Machine Learning-Assisted Screening of Herbal Medicine Extracts as Vaccine Adjuvants.

Authors:  Kou Hioki; Tomoya Hayashi; Yayoi Natsume-Kitatani; Kouji Kobiyama; Burcu Temizoz; Hideo Negishi; Hitomi Kawakami; Hiroyuki Fuchino; Etsushi Kuroda; Cevayir Coban; Nobuo Kawahara; Ken J Ishii
Journal:  Front Immunol       Date:  2022-05-19       Impact factor: 8.786

Review 4.  Nanoparticle vaccines against respiratory syncytial virus.

Authors:  Laura M Stephens; Steven M Varga
Journal:  Future Virol       Date:  2020-11-30       Impact factor: 1.831

Review 5.  Synthetic Biodegradable Microparticle and Nanoparticle Vaccines against the Respiratory Syncytial Virus.

Authors:  Patricia A Jorquera; Ralph A Tripp
Journal:  Vaccines (Basel)       Date:  2016-12-02

6.  Fabrication of optimized skin biomimics for improved interfacial retention of cosmetic emulsions.

Authors:  Georgios Gkotsis; Jonathan James Stanley Rickard; Anju Brooker; Serafim Bakalis; Liam M Grover; Pola Goldberg Oppenheimer
Journal:  J R Soc Interface       Date:  2018-06       Impact factor: 4.118

7.  Novel Formulation of Fusidic Acid Incorporated into a Myrrh-Oil-Based Nanoemulgel for the Enhancement of Skin Bacterial Infection Treatment.

Authors:  Mervt M Almostafa; Heba S Elsewedy; Tamer M Shehata; Wafaa E Soliman
Journal:  Gels       Date:  2022-04-15

8.  Using Dual Toll-like Receptor Agonism to Drive Th1-Biased Response in a Squalene- and α-Tocopherol-Containing Emulsion for a More Effective SARS-CoV-2 Vaccine.

Authors:  Kristopher K Short; Stephanie K Lathrop; Clara J Davison; Haley A Partlow; Johnathan A Kaiser; Rebekah D Tee; Elizabeth B Lorentz; Jay T Evans; David J Burkhart
Journal:  Pharmaceutics       Date:  2022-07-12       Impact factor: 6.525

9.  Novel Multifunctional Biosurfactant Obtained from Corn as a Stabilizing Agent for Antidandruff Formulations Based on Zn Pyrithione Powder.

Authors:  Myriam Rincón-Fontán; Lorena Rodríguez-López; Xanel Vecino; Jose M Cruz; Ana B Moldes
Journal:  ACS Omega       Date:  2020-03-16

10.  Quality of Emulsions Based on Modified Watermelon Seed Oil, Stabilized with Orange Fibres.

Authors:  Małgorzata Kowalska; Anna Żbikowska; Magdalena Woźniak; Aleksandra Amanowicz
Journal:  Molecules       Date:  2022-01-14       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.